CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology

 
• By Sue Sutter

US FDA has received a total of 19 reports of T-cell malignancy involving BCMA- or CD19-directed autologous CAR-T cell immunotherapies and is evaluating the need for regulatory action. Focus on lentiviral and retroviral vectors could extend to safety of other types of gene therapies.

Magnifying glass
The US FDA is looking closely at 19 reports of T-cell malignancies with approved CAR-T products. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet